MEDICAL BIO WARFARE DEFENSE PLAN 8 APR 91

File: 970101_sep96_decls1_0010.txt
Page: 0010
Total Pages: 194

Subject: MEDICAL BIO WARFARE DEFENSE PLAN  8 APR 91                      

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003202

Folder Title: MEDICAL BIOLOGICAL WARFARE - BW- DEFENSE PLAN                                                   

Document Number:          2

Folder Seq  #:         25



                                          SE6RE+UNCLASSIFIED




              b.  @ Remaining portion of the vaccines and antitoxin will be
          stored at the
          m              INCTR vaccine storage facility should be operational
          in 2QFY92. Effort was started in FY90 by the Army Medical
          Department.

          6. (U) Store quantities of licensed products in bulk to maximize
          shelf-life. The only licensed products in the inventory are
          anthrax vaccine, smallpox vaccine, and plague vaccine. Licensed
          products held in bulk can be re-tested before final packaging in
          order to ensure potency. Once packaged in multi-dose vials, the
          licensed products have a relatively short shelf-life of one to
          three years. On the other hand, investigational new drug (IND)
          products can be held indefinitely since they are bottled and
          labeled with the date of 'manufacture but have no expiration date.
          It may be feasible to keep all the IND products bottled in
          multi-dose vials.

          7. (U) Maintain industrial base for vaccine and antitoxin
          production by establishing annual requirements in para 3. Also
          maintain CONUS industrial base for production to ensure treatment
          capability against anthrax. Industrial base for other vaccines and
          biologicals should be maintained.

          8. (U) Finalize the TRADOC boarding process for the Theater Army
          Medical Laboratory. This laboratory is specifically designed to
          identify BW and chemical warfare agents used against U.S. Forces in
          the theater of operations and provides vital information in the
          diagnosis and treatment of BW and CW casualties.

          9.  @ Establish a MOU between Department of Defense and
          621@                             to exchange suspected BW samples
            )r OU
          tor aoutle verification of BW attack on either country's forces.
s results plus other supportive data would provide solid
          evidence and an irrefutable basis for retaliation against opposing
          force(s) using BW agents. U.S. and           have internationally
          recognized laboratories for definitive i en ification of BW
          agents. Confirmatory results from either labs of BW agent present
          is definitive proof. confirmatory results from both labs of BW
          agent present is irrefutable proof before the international
          community.

          10. (U) Make vaccines and antitoxins available to select allies
          through Foreign Military Sales to avoid future geopolitical
          vaccination issues and to develop a deterrence against the use of
          such BW agents in future wars.


                                             3
                                         UNCLASSIFIED
                                                ror

Document 194 f:/Week-36/BX003202/MEDICAL BIOLOGICAL WARFARE - BW- DEFENSE PLAN/medical bio warfare defense plan 8 apr 91:1224960931152
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003202
Unit = OTSG
Parent Organization = HSC
Folder Title = MEDICAL BIOLOGICAL WARFARE - BW- DEFENSE PLAN
Folder Seq # = 25
Subject = MEDICAL BIO WARFARE DEFENSE PLAN 8 APR 91
Document Seq # = 2
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 24-DEC-1996